Quarterly Results- overall
Annual Results- Scale
Annual Results- Liquidity
Annual Results- Profitability/Return
Annual Results- Valuation
External Ecosystem
Sector
Major Subsidiaries/Associates
Key Clients
Products
Products
Product details
Operations
Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
|
From Rural Aspirations to Pharmaceutical Careers: Granules India’s Pharma Pathashala Creates Pathways for Youth
Read More
|
|
Granules India Allots 2.49 Crore Shares to Promoters Following Warrant Conversion
Read More
|
|
Granules India Details Preferential Allotment of 2.5 Crore Warrants to Promoters
Read More
|
|
Granules India promoter group stake rises to 37.39% after warrant conversion
Read More
|
|
Granules India promoter sells 1.72 crore shares in block deal
Read More
|
|
Granules India: ????????? ?? ???? ?? ???? ????, **2.5 ?????** ??????? ????
Read More
|
|
Granules India Mexico Subsidiary: GRANULES Expands Globally
Read More
|
|
Trade Spotlight: How should you trade Granules India, Federal Bank, Zydus Lifesciences, Firstsource Solutions, and others on October 23?
Read More
|
|
What Granules India Doubters Got Wrong
Read More
|
|
Granules India Gagillapur FDA Inspection and Manufacturing Compliance Explained
Read More
|
|
US FDA Starts Inspection at Granules India’s Telangana Plant
Read More
|
|
Granules India eyes sole first-to-file status for Ruxolitinib drug Application for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed I with the US FDA.
Read More
|
|
Granules India Share Price Rise Streak: price, valuation
Read More
|
|
Granules India Eyes 180-Day Exclusivity on Generic Ruxolitinib
Read More
|
|
Granules India eyes potential 180-day US exclusivity for Ruxolitinib ER
Read More
|
|
Granules India plans ?2k cr investment to drive growth
Read More
|
|
Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.
Read More
|
|
Granules India files Paragraph IV certification for Ruxolitinib Extended-Release Tablets
Read More
|
|
Granules India plans ?2,000 crore investment to drive growth in complex generics, oncology, and peptide C
Read More
|
|
Granules India incorporates wholly owned subsidiary in Brazil
Read More
|
|
Granules India Share Price Fall Streak after 4.58% drop
Read More
|